Long-Term Use of Tirzepatide Sustains Weight Reduction in Adults with Obesity

A phase 3 clinical trial evaluated the effect of tirzepatide, a once-weekly subcutaneous medication, on the maintenance of weight reduction in individuals with obesity or overweight. After 36 weeks of treatment, participants experienced a mean weight reduction of 20.9%. During the subsequent 52-week double-blind period, those who continued tirzepatide treatment maintained and further reduced their weight, while those who switched to placebo experienced a 14% weight regain. The study highlights the importance of continued treatment with tirzepatide in sustaining weight loss and preventing weight regain in individuals with obesity or overweight.